Microbot Medical Aligns with AMA Policy to Boost Radiation Protection in Endovascular Procedures
Event summary
- Microbot Medical aligns with the AMA's 2025 policy to expand radiation protection for healthcare professionals.
- LIBERTY System demonstrated a 92% relative reduction in radiation exposure in the ACCESS-PVI Study.
- Microbot plans Full Market Release of LIBERTY at the SIR conference in April 2026.
- Prolonged radiation exposure contributes to staffing shortages in interventional radiology.
The big picture
The AMA's policy underscores the growing need for safer endovascular procedures, aligning with Microbot's LIBERTY System's value proposition. Radiation exposure is a critical factor in staffing shortages, particularly affecting women in the field. Microbot's strategic alignment with the AMA policy positions it to capitalize on the demand for safer, more efficient endovascular solutions.
What we're watching
- Market Adoption
- The pace at which LIBERTY gains market traction post-Full Market Release in April 2026.
- Regulatory Alignment
- How Microbot leverages the AMA policy to strengthen its value proposition in radiation protection.
- Competitive Positioning
- Whether LIBERTY can sustain its differentiation in reducing radiation exposure and physical strain.
Related topics